Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price rose 1.4% during mid-day trading on Friday . The stock traded as high as $23.58 and last traded at $23.45. Approximately 6,965,677 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 40,851,239 shares. The stock had previously closed at $23.12.
Analysts Set New Price Targets
PFE has been the topic of several recent analyst reports. The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.
Read Our Latest Analysis on Pfizer
Pfizer Trading Up 1.0%
The firm has a market cap of $132.81 billion, a P/E ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. The firm's fifty day moving average is $22.95 and its two-hundred day moving average is $25.00. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.82 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.36%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.
Hedge Funds Weigh In On Pfizer
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rialto Wealth Management LLC purchased a new position in Pfizer during the fourth quarter valued at $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC lifted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter worth about $27,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
